ADM’s DE111 spore-forming probiotic receives approval from Australia’s Therapeutic Goods Administration
ADM announced that its spore-forming probiotic DE111 (Bacillus subtilis) has received official approval from the Therapeutic Goods Administration (TGA), which is a part of the Australian Department of Health.
Photo © Shutterstock.com/AlexLMX
ADM announced that its spore-forming probiotic DE111 (Bacillus subtilis) has received official approval from the Therapeutic Goods Administration (TGA), which is a part of the Australian Department of Health.
“This is an important milestone for ADM, as it marks the first Bacillus subtilis strain to be approved by the TGA in Australia,” said Helen Hu, president of health & wellness APAC at ADM, in a press release. “By expanding access to DE111, we’re facilitating new innovation possibilities for our Australian customers, enabling the development of pioneering gut health-supporting products. Additionally, the continued approval of DE111 by important government authorities demonstrates its high quality, safety and alignment with strict regulatory standards.”
Citing figures from FMCG Gurus’ 2022 Digestive Health Global Study, 81% of Australian consumers recognize the link between digestive health and overall well-being , and 76% recognize the connection between digestive health and immune health. Additionally, 64% of Australian consumers stated that they have used probiotics to address digestive health concerns in the previous 12 months.
This announcement represents ADM’s continued expansion into new regions. Most recently, DE111 received approval from the Chinese National Health Commission.
